Technology evaluation: HspE7 (Stressgen).
Article Details
- CitationCopy to clipboard
Maciag PC, Paterson Y
Technology evaluation: HspE7 (Stressgen).
Curr Opin Mol Ther. 2005 Jun;7(3):256-63.
- PubMed ID
- 15977424 [ View in PubMed]
- Abstract
Stressgen is developing HspE7, a recombinant fusion protein comprising the human papillomavirus (HPV) E7 antigen and the heat shock protein Hsp65 from Mycobacterium bovis, as a potential therapy for conditions associated with HPV infection. This therapy is currently undergoing phase III clinical trials.
DrugBank Data that Cites this Article
- Drugs